ArticleFrontiers in oncology2023

Real-world study of PD-1/L1 immune checkpoint inhibitors for advanced non-small cell lung cancer after resistance to EGFR-TKIs.

Kunchen Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.